Business Wire

SES’s Next-Gen NGSO System Readies for Launch with 8 Initial O3b mPOWER Satellite Ground Stations

28.4.2021 09:50:00 EEST | Business Wire | Press release

Share

SES announced today that it has signed agreements with key infrastructure service providers around the world to build its eight initial O3b mPOWER satellite ground stations. Construction has already started on these advanced technology satellite ground stations, which will become operational in the second half of this year. The eight sites will provide telemetry, tracking and control capabilities to enable SES’s management of the constellation. They will also be leveraged to raise the satellites into the right orbit after the scheduled launches.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427006193/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SES’s Next-Gen NGSO System Readies for Launch with 8 Initial O3b mPOWER Satellite Ground Stations (Photo: Business Wire)

As previously announced, two of the satellite ground stations are located at Dubbo, NSW, Australia (operated by Pivotel) and Thermopylae, Greece (operated by OTE). Other locations include Merredin, Perth, Australia; Phoenix, Arizona, US; Chile; the United Arab Emirates; Senegal as well as SES’s own satellite ground station in Hawaii. Four out of the eight sites will be co-located and operated with Microsoft’s Azure data centres; the one-hop connectivity to the cloud from remote sites will provide O3b mPOWER customers the ability to optimise business operations with significant flexibility and agility.

O3b mPOWER is SES’s next-generation Medium Earth Orbit (MEO) system. Building on the success of O3b, each of the 11 high-throughput, low-latency O3b mPOWER satellites will deliver high-speed connectivity services from tens of megabits to multiple gigabits per second, providing fibre-like connectivity to customers globally.

The O3b mPOWER satellite ground stations have many technically advanced features compared to the existing O3b satellite ground station. They include a new generation of fast-install 5.5-metre carbon fibre antennas which can be installed without the need for expensive and time-consuming photogrammetry. In addition, they will utilise energy-efficient solid-state power amplifiers, and a low electrical load for the antenna control unit (ACU).

The satellite ground stations will use SES’s gateway management system for automated operations and handovers, which will be tightly integrated with SES’s unique resource management capability, Adaptive Resource Control (ARC) and other SES software sub-systems. With this configuration, SES will dynamically manage and optimise space and ground resources to meet the changing needs of its customers. These combined technology advances result in improved efficiency and lower total cost of ownership.

The first three O3b mPOWER satellites are scheduled for launch in the third quarter of this year, with the next three in the first quarter of 2022. After orbit raising, O3b mPOWER will start delivering services in the third quarter of 2022.

Stewart Sanders, Executive Vice President of Technology and O3b mPOWER programme manager at SES, said, “We are thrilled to have chosen these eight locations and construction is underway. We are also deep in discussions with several telco players and operators who are keen to have their own O3b mPOWER satellite ground station. This is particularly exciting, as it means that SES’s provision of a core network of command, control and data gateways will be augmented with a number of customer satellite ground stations; satellite ground stations provisioned according to our customer needs, with regards to location, size and infrastructure requirements. We expect a number of these customer satellite ground stations to include virtualised installations of the cloud at the edge of the deployed networks, thus improving the end-user experience.”

Follow us on:

Read our Blogs >

Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye